Cargando…

Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias such as anemia, neutropenia, or thrombocytopenia, abnormal cellular maturation, and a high risk of progression to acute myeloid leukemia. The bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Bains, Amanpreet Kaur, Behrens Wu, Lena, Rivière, Jennifer, Rother, Sandra, Magno, Valentina, Friedrichs, Jens, Werner, Carsten, Bornhäuser, Martin, Götze, Katharina S., Cross, Michael, Platzbecker, Uwe, Wobus, Manja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492883/
https://www.ncbi.nlm.nih.gov/pubmed/36158640
http://dx.doi.org/10.3389/fonc.2022.961473
_version_ 1784793574657753088
author Bains, Amanpreet Kaur
Behrens Wu, Lena
Rivière, Jennifer
Rother, Sandra
Magno, Valentina
Friedrichs, Jens
Werner, Carsten
Bornhäuser, Martin
Götze, Katharina S.
Cross, Michael
Platzbecker, Uwe
Wobus, Manja
author_facet Bains, Amanpreet Kaur
Behrens Wu, Lena
Rivière, Jennifer
Rother, Sandra
Magno, Valentina
Friedrichs, Jens
Werner, Carsten
Bornhäuser, Martin
Götze, Katharina S.
Cross, Michael
Platzbecker, Uwe
Wobus, Manja
author_sort Bains, Amanpreet Kaur
collection PubMed
description Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias such as anemia, neutropenia, or thrombocytopenia, abnormal cellular maturation, and a high risk of progression to acute myeloid leukemia. The bone marrow microenvironment (BMME) in general and mesenchymal stromal cells (MSCs) in particular contribute to both the initiation and progression of MDS. However, little is known about the role of MSC-derived extracellular matrix (ECM) in this context. Therefore, we performed a comparative analysis of in vitro deposited MSC-derived ECM of different MDS subtypes and healthy controls. Atomic force microscopy analyses demonstrated that MDS ECM was significantly thicker and more compliant than those from healthy MSCs. Scanning electron microscopy showed a dense meshwork of fibrillar bundles connected by numerous smaller structures that span the distance between fibers in MDS ECM. Glycosaminoglycan (GAG) structures were detectable at high abundance in MDS ECM as white, sponge-like arrays on top of the fibrillar network. Quantification by Blyscan assay confirmed these observations, with higher concentrations of sulfated GAGs in MDS ECM. Fluorescent lectin staining with wheat germ agglutinin and peanut agglutinin demonstrated increased deposition of N-acetyl-glucosamine GAGs (hyaluronan (HA) and heparan sulfate) in low risk (LR) MDS ECM. Differential expression of N-acetyl-galactosamine GAGs (chondroitin sulfate, dermatan sulfate) was observed between LR- and high risk (HR)-MDS. Moreover, increased amounts of HA in the matrix of MSCs from LR-MDS patients were found to correlate with enhanced HA synthase 1 mRNA expression in these cells. Stimulation of mononuclear cells from healthy donors with low molecular weight HA resulted in an increased expression of various pro-inflammatory cytokines suggesting a contribution of the ECM to the inflammatory BMME typical of LR-MDS. CD34(+) hematopoietic stem and progenitor cells (HSPCs) displayed an impaired differentiation potential after cultivation on MDS ECM and modified morphology accompanied by decreased integrin expression which mediate cell-matrix interaction. In summary, we provide evidence for structural alterations of the MSC-derived ECM in both LR- and HR-MDS. GAGs may play an important role in this remodeling processes during the malignant transformation which leads to the observed disturbance in the support of normal hematopoiesis.
format Online
Article
Text
id pubmed-9492883
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94928832022-09-23 Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes Bains, Amanpreet Kaur Behrens Wu, Lena Rivière, Jennifer Rother, Sandra Magno, Valentina Friedrichs, Jens Werner, Carsten Bornhäuser, Martin Götze, Katharina S. Cross, Michael Platzbecker, Uwe Wobus, Manja Front Oncol Oncology Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias such as anemia, neutropenia, or thrombocytopenia, abnormal cellular maturation, and a high risk of progression to acute myeloid leukemia. The bone marrow microenvironment (BMME) in general and mesenchymal stromal cells (MSCs) in particular contribute to both the initiation and progression of MDS. However, little is known about the role of MSC-derived extracellular matrix (ECM) in this context. Therefore, we performed a comparative analysis of in vitro deposited MSC-derived ECM of different MDS subtypes and healthy controls. Atomic force microscopy analyses demonstrated that MDS ECM was significantly thicker and more compliant than those from healthy MSCs. Scanning electron microscopy showed a dense meshwork of fibrillar bundles connected by numerous smaller structures that span the distance between fibers in MDS ECM. Glycosaminoglycan (GAG) structures were detectable at high abundance in MDS ECM as white, sponge-like arrays on top of the fibrillar network. Quantification by Blyscan assay confirmed these observations, with higher concentrations of sulfated GAGs in MDS ECM. Fluorescent lectin staining with wheat germ agglutinin and peanut agglutinin demonstrated increased deposition of N-acetyl-glucosamine GAGs (hyaluronan (HA) and heparan sulfate) in low risk (LR) MDS ECM. Differential expression of N-acetyl-galactosamine GAGs (chondroitin sulfate, dermatan sulfate) was observed between LR- and high risk (HR)-MDS. Moreover, increased amounts of HA in the matrix of MSCs from LR-MDS patients were found to correlate with enhanced HA synthase 1 mRNA expression in these cells. Stimulation of mononuclear cells from healthy donors with low molecular weight HA resulted in an increased expression of various pro-inflammatory cytokines suggesting a contribution of the ECM to the inflammatory BMME typical of LR-MDS. CD34(+) hematopoietic stem and progenitor cells (HSPCs) displayed an impaired differentiation potential after cultivation on MDS ECM and modified morphology accompanied by decreased integrin expression which mediate cell-matrix interaction. In summary, we provide evidence for structural alterations of the MSC-derived ECM in both LR- and HR-MDS. GAGs may play an important role in this remodeling processes during the malignant transformation which leads to the observed disturbance in the support of normal hematopoiesis. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9492883/ /pubmed/36158640 http://dx.doi.org/10.3389/fonc.2022.961473 Text en Copyright © 2022 Bains, Behrens Wu, Rivière, Rother, Magno, Friedrichs, Werner, Bornhäuser, Götze, Cross, Platzbecker and Wobus https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bains, Amanpreet Kaur
Behrens Wu, Lena
Rivière, Jennifer
Rother, Sandra
Magno, Valentina
Friedrichs, Jens
Werner, Carsten
Bornhäuser, Martin
Götze, Katharina S.
Cross, Michael
Platzbecker, Uwe
Wobus, Manja
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
title Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
title_full Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
title_fullStr Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
title_full_unstemmed Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
title_short Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
title_sort bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in myelodysplastic syndromes
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492883/
https://www.ncbi.nlm.nih.gov/pubmed/36158640
http://dx.doi.org/10.3389/fonc.2022.961473
work_keys_str_mv AT bainsamanpreetkaur bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT behrenswulena bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT rivierejennifer bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT rothersandra bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT magnovalentina bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT friedrichsjens bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT wernercarsten bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT bornhausermartin bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT gotzekatharinas bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT crossmichael bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT platzbeckeruwe bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes
AT wobusmanja bonemarrowmesenchymalstromalcellderivedextracellularmatrixdisplaysalteredglycosaminoglycanstructureandimpairedfunctionalityinmyelodysplasticsyndromes